Superworth

Talphera revenue TLPH

Sales by quarter and over the last twelve months, from 2012.

Last 12 months, to Jun 30, 2026
$1K
Latest quarter, Q2 FY26
$0
Fiscal year 2025
$28K

Talphera's revenue was $1K over the twelve months to Jun 30, 2026, down 96% on a year earlier.

In its latest quarter, Q2 FY26, it was $0.

Over the five fiscal years to FY2025 it shrank 65% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$28Kn/a
FY2024$0n/a
FY2023n/an/a
FY2022$442K−84%
FY2021$2.8M−48%
FY2020$5.4M+137%
FY2019$2.3M+6%
FY2018$2.2M−73%
FY2017$8M−54%
FY2016$17.4M−10%
FY2015$19.3M+269%
FY2014$5.2M−82%
FY2013$29.5M+1132%
FY2012$2.4Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$0n/a$1K
Q1 FY26$0−100%$1K
Q4 FY25$0n/a$28K
Q3 FY25$1Kn/a$28K
Q2 FY25$0n/a$27K
Q1 FY25$27Kn/a$27K
Q4 FY24$0−100%$0
Q3 FY24$0−100%$281K
Q2 FY24$0−100%$398K
Q1 FY24$0n/a$651K
Q4 FY23$281Kn/an/a
Q3 FY23$117Kn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Talphera's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
TLPHTalphera$1K−96% a year
SPROSpero Therapeutics$47M−3% a year
ATNMActinium Pharmaceuticalsn/m
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
Peer median$249.6M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Talphera

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.